Loading, Please Wait...
SCOTTSDALE, Ariz., March 29, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced the appointment of Jeffrey Rassás as Executive Chairman of the Board of Directors. Rassás has resigned as Chief Strategic Officer of the Company to take on his new role as Executive Chairman.
As Executive Chairman, Rassás will continue as part of the Company’s C-Suite and shall maintain his operational responsibilities working closely with the Item 9 Labs management team to provide guidance and advisement to the CEO, management and employees.
Rassás is a twenty-year veteran of entrepreneurial ventures and business management. He has extensive experience in funding, leading, developing and performing corporate turnarounds. Rassás has held executive positions at numerous private and public start-up ventures across a variety of industries.
“Item 9 Labs is positioned to be a leader in the cannabis sector with a world class management team, each of whom is well versed in their particular fields and roles. Our strategic plan is aggressive and what determines success is execution over ideas,” said Rassás. “As Executive Chairman it will be my responsibility to work closely with this brilliant team to execute our growth strategy around acquisitions, organic activation of current and applied for state licenses and joint ventures.”
The Company has already commenced its growth plans with the recent acquisition of cannabis consulting firm Dispensary Permits, which resulted in the appointment of CEO Sara Gullickson, as well as the recent addition of medical cannabis executives Donald Burton and Larry K. Lemons to the advisory board.
“My goal in the next six months is to ensure our board consists of a vibrant and diverse group of qualified individuals. The Company’s focus is to build a healthy balanced board consisting of cannabis industry experts, seasoned business professionals, and respected financial leaders,” stated Gullickson.
Item 9 Labs is focused on laying a rock solid foundation and determined to deliver results.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Item 9 Labs Corp.